Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Research Oriented-companies Shake Up Generics Market with Established Products
January 16, 2012
- Taiyo to Be Core of Teva’s Operations in Japan
January 16, 2012
- Nichi-Iko Will Soon Decide on Independent or Joint PI Trial for Remicade Biosimilar: President Tamura
January 16, 2012
- Otsuka to Focus on CNS Field, Ending Collaboration in Immunology, Inflammation with UCB
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 15, 2012
- Nichi-Iko Posts Record-High Sales, Profits in FY2011
January 13, 2012
- Pfizer to Strengthen Role of Manufacturing Division by Spin-Off, Utilizing Its Formulation Technology
January 13, 2012
- Hisamitsu: Sales Up 1.2% Due to Favorable Performance of Overseas Subsidiaries
January 13, 2012
- Major Dispensing Pharmacies, Intermediary Companies Aggressively Seek M&A
January 12, 2012
- Survey Shows Astellas Website Most Frequently Accessed by Doctors
January 12, 2012
- Barclays Capital Report Mentions Tivozanib, Raises Astellas Pharma’s Target Stock Price
January 12, 2012
- Interprotein, Takeda Sign Collaboration Agreement on Molecular Design for PPI Modulators
January 12, 2012
- Sales of Ethical Drugs Up 5.2% in November: Crecon Report
January 12, 2012
- Administration of OTSA101 Started in Trial for Synovial Sarcoma: OncoTherapy
January 12, 2012
- Dispensing Point Services Should Continue: Mr Arai of Sugi HD
January 12, 2012
- Current Pollinosis Treatments Least Effective at Relieving Nasal Congestion: MSD
January 12, 2012
- Kyowa Kirin President Matsuda Aims for Global Presence in Biosimilar Business
January 11, 2012
- DSP to Change Brand Name of Almarl to Avoid Confusion
January 11, 2012
- Kyowa Hakko Kirin to Develop Expert MRs to Boost Cancer Field
January 11, 2012
- Nipro to Set Up Pharmaceutical Plant in Vietnam for Contract Manufacturing of Generics
January 11, 2012
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…